BR

Black Rose Industries Ltd

Q4 FY26Chemicals & Petrochemicals

Black Rose Industries Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹114
Market cap₹543 Cr
P/E18.9
Updated23 Sept 2026
Read4 min read

What the Q4 FY26 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned

The short version

The company targets sustained growth in volumes and revenues through both distribution and manufacturing. The company aims for sustained growth with good margins overall for FY27, supported by increasing volumes and operational efficiencies.

From Black Rose Industries Ltd's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Moderate growth
  • The company targets sustained growth in volumes and revenues through both distribution and manufacturing.
  • New product additions in both segments are expected to drive topline growth.
  • Capacity expansions and commercialization of pipeline projects (e.g., PAM solid) will add to volumes and revenues in FY27 and FY28.
  • Export demand, particularly for acrylamide products, is picking up with registrations like REACH and KKDIK aiding market penetration.
  • Market uncertainties remain, but the company is optimistic about increased utilization and sales despite global challenges.
  • Initiatives to increase export sales, which generally have better profitability, are underway.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Black Rose Industries Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • PAM solid project has advanced to the piloting stage with commercialization expected during FY26.
  • Specialty amines project is progressing as planned in collaboration with Koei Chemicals Company, with a decision anticipated during the current year.
  • The company’s R&D team, based at the new laboratory in Navi Mumbai, is focused on new innovations and developing downstream acrylamide products to expand the manufacturing portfolio.
  • Strategic shift away from ceramic binder business to focus on strengthening upstream acrylamide and higher-value applications.

2 more points management made on capital expenditure plans

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

5x potential
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Black Rose Industries Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript of the FY26 Earnings Webinar for Black Rose Industries Ltd. does not provide specific details on the current or expected order book or pending orders. However, related insights include: - There is a "strong order pipeline" in merchant exports expected to convert into healthy performance in Q1 FY27. - The company is focusing on new product additions and expanding its customer base to drive revenue growth. - Export demand for acrylamide products has started to pick up in the second half of the current quarter.

2 more points management made on order book & pipeline

Black Rose Industries Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹104 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Vipul Organics Ltd (Q4 FY26)

    Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…

  • Chemfab Alkalis Ltd (Q4 FY26)

    Chlor Alkali segment: ₹55.63 crore (down 1.21% YoY from ₹56.31 crore) . Key concall takeaways from Chemfab Alkalis Ltd's Q4 FY26 earnings call — and how it…

  • Sudarshan Pharma Industries Ltd (Q4 FY26)

    Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) . Key concall takeaways from Sudarshan Pharma Industries Ltd's Q4 FY26 earnings call — and how…

  • Innovassynth Technologies (India) Ltd (Q4 FY26)

    Order book improved by approximately INR 60 crore during the quarter, indicating strong customer demand and revenue visibility. Key concall takeaways from…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Black Rose Industries Ltd Q4 FY26 results?

The company targets sustained growth in volumes and revenues through both distribution and manufacturing. The company aims for sustained growth with good margins overall for FY27, supported by increasing volumes and operational efficiencies.

What is Black Rose Industries Ltd share price analysis?

Black Rose Industries Ltd currently shows a below-average growth signal. The stock trades at a P/E of 18.9 with a market cap of ₹543 Cr. Investors should review the full earnings analysis for detailed insights.

Is Black Rose Industries Ltd planning capital expenditure?

PAM solid project has advanced to the piloting stage with commercialization expected during FY26.

Keep Black Rose Industries Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.